JP2017521364A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017521364A5 JP2017521364A5 JP2016568435A JP2016568435A JP2017521364A5 JP 2017521364 A5 JP2017521364 A5 JP 2017521364A5 JP 2016568435 A JP2016568435 A JP 2016568435A JP 2016568435 A JP2016568435 A JP 2016568435A JP 2017521364 A5 JP2017521364 A5 JP 2017521364A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- compound
- pharmaceutical composition
- disorder
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 21
- 125000001072 heteroaryl group Chemical group 0.000 claims description 5
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000024254 Delusional disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000003920 cognitive function Effects 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037765 diseases and disorders Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000007658 neurological function Effects 0.000 claims 1
- 208000002851 paranoid schizophrenia Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 229910052717 sulfur Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL408251A PL408251A1 (pl) | 2014-05-19 | 2014-05-19 | Skondensowane pochodne triazolu jako inhibitory fosfodiesterazy 10A |
| PLP.408251 | 2014-05-19 | ||
| PCT/IB2015/053549 WO2015177688A1 (en) | 2014-05-19 | 2015-05-14 | Fused triazole derivatives as phosphodiesterase 10a inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017521364A JP2017521364A (ja) | 2017-08-03 |
| JP2017521364A5 true JP2017521364A5 (enExample) | 2018-06-21 |
| JP6455947B2 JP6455947B2 (ja) | 2019-01-23 |
Family
ID=53434395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016568435A Active JP6455947B2 (ja) | 2014-05-19 | 2015-05-14 | ホスホジエステラーゼ１０ａインヒビターとしての縮合トリアゾール誘導体 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10138245B2 (enExample) |
| EP (1) | EP3145930B1 (enExample) |
| JP (1) | JP6455947B2 (enExample) |
| KR (1) | KR102404650B1 (enExample) |
| CN (1) | CN106459060B (enExample) |
| AU (1) | AU2015263013B2 (enExample) |
| CA (1) | CA2946258C (enExample) |
| DK (1) | DK3145930T3 (enExample) |
| EA (1) | EA030330B9 (enExample) |
| ES (1) | ES2688084T3 (enExample) |
| HR (1) | HRP20181027T1 (enExample) |
| HU (1) | HUE039847T2 (enExample) |
| MX (1) | MX367647B (enExample) |
| PL (2) | PL408251A1 (enExample) |
| PT (1) | PT3145930T (enExample) |
| SI (1) | SI3145930T1 (enExample) |
| WO (1) | WO2015177688A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| WO2017007301A1 (en) * | 2015-07-06 | 2017-01-12 | Universiti Sains Malaysia | Compound and method for inhibiting sirtuin activities |
| KR102587382B1 (ko) * | 2016-04-29 | 2023-10-12 | 솔루스첨단소재 주식회사 | 유기 발광 화합물 및 이를 이용한 유기 전계 발광 소자 |
| CN111410657B (zh) * | 2019-01-08 | 2024-05-21 | 北京鼎材科技有限公司 | 一种发光材料及其应用 |
| WO2025160629A1 (en) * | 2024-01-31 | 2025-08-07 | Certa Therapeutics Pty Ltd | Proton sensing gpcr modulators |
| US20250276984A1 (en) * | 2024-02-20 | 2025-09-04 | Iambic Therapeutics, Inc. | Solid state forms of her2 inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2694983A1 (en) * | 2007-07-17 | 2009-01-22 | Combinatorx, Incorporated | Treatments of b-cell proliferative disorders |
| TWI501965B (zh) * | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物 |
| US8410117B2 (en) * | 2010-03-26 | 2013-04-02 | Hoffmann-La Roche Inc. | Imidazopyrimidine derivatives |
| US8975276B2 (en) | 2011-06-29 | 2015-03-10 | Bristol-Myers Squibb Company | Inhibitors of PDE10 |
-
2014
- 2014-05-19 PL PL408251A patent/PL408251A1/pl unknown
-
2015
- 2015-05-14 EP EP15730261.3A patent/EP3145930B1/en active Active
- 2015-05-14 PT PT15730261T patent/PT3145930T/pt unknown
- 2015-05-14 CA CA2946258A patent/CA2946258C/en active Active
- 2015-05-14 ES ES15730261.3T patent/ES2688084T3/es active Active
- 2015-05-14 AU AU2015263013A patent/AU2015263013B2/en active Active
- 2015-05-14 EA EA201692264A patent/EA030330B9/ru not_active IP Right Cessation
- 2015-05-14 KR KR1020167035389A patent/KR102404650B1/ko active Active
- 2015-05-14 DK DK15730261.3T patent/DK3145930T3/en active
- 2015-05-14 CN CN201580025963.XA patent/CN106459060B/zh active Active
- 2015-05-14 US US15/311,698 patent/US10138245B2/en active Active
- 2015-05-14 HR HRP20181027TT patent/HRP20181027T1/hr unknown
- 2015-05-14 MX MX2016015180A patent/MX367647B/es active IP Right Grant
- 2015-05-14 JP JP2016568435A patent/JP6455947B2/ja active Active
- 2015-05-14 HU HUE15730261A patent/HUE039847T2/hu unknown
- 2015-05-14 SI SI201530382T patent/SI3145930T1/sl unknown
- 2015-05-14 WO PCT/IB2015/053549 patent/WO2015177688A1/en not_active Ceased
- 2015-05-14 PL PL15730261T patent/PL3145930T3/pl unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017521364A5 (enExample) | ||
| ES2949404T3 (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP | |
| JP2016531113A5 (enExample) | ||
| JP2017537940A5 (enExample) | ||
| RU2733750C2 (ru) | Производные карбоксизамещенных (гетеро)ароматических колец, способ их получения и применение | |
| JP2017538689A5 (enExample) | ||
| JP2006509749A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| JP2017514830A5 (enExample) | ||
| JP2011037841A5 (enExample) | ||
| JP2014507455A5 (enExample) | ||
| RU2012116877A (ru) | Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы | |
| ES2957692T3 (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP | |
| JP2014506907A5 (enExample) | ||
| JP2017524733A5 (enExample) | ||
| JP2017505293A5 (enExample) | ||
| JP2015508092A5 (enExample) | ||
| JP2020512337A5 (enExample) | ||
| JP2021046404A5 (enExample) | ||
| RU2014113679A (ru) | N-(2-амино-6,6-дифтор-4,4а,5,6,7,7а-гексагидро-циклопента[e][1,3]оксазин-4-ил)-фенил)-амиды в качестве ингибиторов бета-секретазы 1 | |
| HRP20220472T1 (hr) | Novi derivati heteroarilamida kao selektivni inhibitori histonskih deacetilaza 1 i 2 (hdac1-2) | |
| HRP20181027T1 (hr) | Derivati fuzioniranog triazola kao inhibitori fosfodiesteraze 10a | |
| JP2015526453A5 (enExample) | ||
| JP2019532067A5 (enExample) | ||
| JP2019526546A5 (enExample) |